Xbrane Biopharma : Invitation to presentation of Xbrane Biopharma's interim report January - March 2024 on May 16, 2024
May 13, 2024 at 04:20 am EDT
Share
English
Swedish
Published: 2024-05-13 10:10:00 CEST
Xbrane Biopharma AB
Investor News
Invitation to presentation of Xbrane Biopharma's interim report January - March 2024 on May 16, 2024
Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on Thursday, May 16th, 2024, at 09.00 a.m. CET. Xbrane will publish the company's interim report January - March 2024, on Thursday, May 16, 2024, at 8.00 a.m. CET.
Martin Åmark, CEO, and Anette Lindqvist, CFO/IR, will present the interim report January - March 2024, followed by a Q&A session. The presentation will be in English. To attend, please follow the link below:
If you wish to participate via webcast, please use the link below. Via the webcast you can ask written questions.
If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 26 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com
Attachments:
Invitation to presentation of Xbrane Biopharmas interim report January - March 2024 on May 16 2024.pdf
This news release was distributed by Company News System, www.nasdaqomxnordic.com/news/marketnotices
To subscribe on regulatory news from this company, go to the subscription page
Attachments
Original Link
Permalink
Disclaimer
Xbrane Biopharma AB published this content on
13 May 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
13 May 2024 08:19:05 UTC.
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
XBRANE BIOPHARMA AB 
